REG - Tate & Lyle PLC - Completion of Combination Tate & Lyle and CP Kelco

Tate & LyleAnnouncement

15/11/2024 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241115:nRSO4911Ma&default-theme=true

RNS Number : 4911M  Tate & Lyle PLC  15 November 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, INTO OR
FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

FOR IMMEDIATE RELEASE

 

15 November 2024

Tate & Lyle PLC

('Tate & Lyle' or the 'Company')

 

Completion of combination of Tate & Lyle and CP Kelco to create

a leading global speciality food and beverage solutions business

 

Further to the announcements of 20 June 2024 and 3 October 2024, Tate &
Lyle announces that on 15 November 2024 it completed the acquisition of the
entire issued share capital of (i) CP Kelco U.S.; (ii) CP Kelco China; and
(iii) CP Kelco ApS together with each of their respective subsidiaries
(together 'CP Kelco') a leading provider of pectin, speciality gums and other
nature-based ingredients, from J.M. Huber Corporation ('Huber') (the
'Transaction').

 

There has been no material change affecting any matters contained in Tate
& Lyle's announcements relating to the Transaction of 20 June 2024 and 3
October 2024.

 

Nick Hampton, Chief Executive Officer of Tate & Lyle, commented:

 

"Today, as we complete the combination with CP Kelco, we begin a new chapter
in Tate & Lyle's long and rich history.

 

We are delighted to welcome our new colleagues from CP Kelco, as well as its
customers and partners to Tate & Lyle. This is an exciting time for both
businesses as we come together to create a new and compelling proposition for
our customers. With its unique portfolio of ingredients and solutions
capabilities, and leading positions across  sweetening, mouthfeel and
fortification, the combined business is perfectly positioned to support
customers as they look to meet growing global consumer demand for healthier,
tastier and more sustainable food and drink.

 

My thanks to all those who worked so tirelessly and diligently across Tate
& Lyle and CP Kelco to complete this transaction.  I would also like to
thank Gretchen McClain and the team at Huber for their immense contribution,
and to welcome Glenn and Cláudia to the Tate & Lyle Board.

 

The growth potential of the new business is substantial, and we look forward
to the future with great excitement and confidence."

 

Board changes

 

In accordance with the relationship agreement entered into between Tate &
Lyle and Huber (the 'Relationship Agreement'), Huber is currently entitled to
nominate two non-executive directors to the board of Tate & Lyle (the
'Board') with effect from the completion of the Transaction.

 

Tate & Lyle is pleased to announce the appointment of Glenn M. Fish,
Executive Vice President & Chief Financial Officer of Huber, and Cláudia
Vaz de Lestapis, Executive Vice President, General Counsel and Corporate
Secretary of Huber, to the Board as non-executive directors, with effect from
15 November 2024.  For more information see Appendix 1.

Issuance of Consideration Shares to Huber

 

In accordance with the terms of the Transaction, the Company has issued and
allotted 75,000,000 new fully paid Tate & Lyle ordinary shares to Huber
(the 'Consideration Shares') as part consideration for the Transaction.

 

Huber is now a significant long-term shareholder of Tate & Lyle, owning
approximately 16% of the Company's share capital immediately following
completion of the Transaction.

 

Applications have been made for the Consideration Shares to be admitted to
listing on the Equity Shares (Commercial Companies) Category of the Financial
Conduct Authority's Official List and to trading on the London Stock
Exchange's main market for listed securities ('Admission'). It is currently
anticipated that Admission will occur at 08:00 (UK Time) on 18 November 2024.

 

Total Voting Rights

 

Following the issuance and allotment of the Consideration Shares, and in
accordance with the FCA's Disclosure Guidance and Transparency Rules 5.6.1R
and 5.6.1AR, the Company hereby notifies the market that the Company's issued
share capital as at 15 November 2024 consists of 476,722,733 ordinary shares
('Ordinary Shares'), including 24,813,400(1) Ordinary Shares held in Treasury.
Ordinary Shares held in Treasury do not carry any voting rights.

 

Therefore, following the issuance and allotment of the Consideration Shares,
the total number of voting rights in the Company is 451,909,333 and this
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, Tate & Lyle under the Disclosure Guidance
and Transparency Rules.

 

 

-------------------------------------------------------------------------------------------------

1.   Excludes Ordinary Shares that have been, or may be, repurchased by the
Company on 15 November 2024 as part of its ongoing share buyback programme.

 

 

For more information contact:

 

For Tate & Lyle PLC

 

Investors and analysts

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Media

Nick Hasell, FTI Consulting

Tel: Mobile: +44 (0) 7825 523 383

Tel: Office: +44 (0) 203 727 1340

Email: tate@fticonsulting.com

 

For Huber:

 

Lea Volpe

Vice President, Communications & Community Relations

Tel: Mobile: +1 404 956 4470

 

Information on Tate & Lyle

 

Supported by our 160-year history of ingredient innovation, we partner with
customers to provide consumers with healthier and tastier choices when they
eat and drink. We are proud that millions of people around the world consume
products containing our ingredients every day. Through our expertise in
sweetening, fortification, and texture, we develop ingredient solutions which
reduce sugar, calories, and fat, add fibre and protein, and provide texture
and stability in categories including beverages, dairy, bakery, snacks, soups,
sauces, and dressings.

 

We have more than 3,300 employees working in around 58 locations serving
customers across 121 countries. Science, Solutions, Society is our brand
promise and how we will achieve our purpose of Transforming Lives Through the
Science of Food. By living our purpose we believe we can successfully grow our
business and have a positive impact on society. We live our purpose in three
ways, by supporting healthy living, building thriving communities and caring
for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol
TATE.L. American Depositary Receipts trade under TATYY. In the year to 31
March 2024, Tate & Lyle revenue from continuing operations totalled £1.65
billion.

 

Tate & Lyle PLC's LEI number is: 2138008K14474WPKZ244.

 

For more information, please visit https://www.tateandlyle.com
(https://www.tateandlyle.com/)  or follow Tate & Lyle on LinkedIn
(https://www.linkedin.com/company/tate-&-lyle) , X
(https://twitter.com/tateandlyleplc) (Twitter), Facebook
(https://www.facebook.com/TateandLyleCommunity)  or YouTube
(https://www.youtube.com/c/TateLylePLC) .

 

 

Information on CP Kelco

 

CP Kelco is a nature-based ingredient solutions company with approximately 90
years of experience working with food, beverage, consumer and industrial
products manufacturers worldwide. It produces an extensive range of
high-quality, plant-based and fermentation-derived ingredients to provide
tailored solutions for its customers.

 

It is committed to providing responsibly sourced and produced ingredients for
its customers with whom it collaborates closely through a global team of
scientists and applications experts.  Key products include pectin,
carrageenan, gellan gum, xanthan gum, diutan gum, fermentation-derived
cellulose, refined locust bean gum, microparticulated whey protein concentrate
and citrus fibre.

 

CP Kelco has a strong global talent base of around 1,700 employees working out
of seven manufacturing facilities, two global innovation centres and nine
regional application centres. The business is headquartered in Atlanta,
Georgia, US.  CP Kelco is committed to safety, quality and sustainability,
and to deliver a positive social impact.

 

Information on Huber

 

Huber, headquartered in Atlanta, Georgia (US), operates, partners and invests
in a diverse portfolio of businesses. Huber operates Huber Engineered
Materials, Huber Engineered Woods and Huber Resources Corp., is an invested
shareholder in Tate & Lyle (LSE: TATE.L), and an investor in KaMin and
timberlands in the US.

 

With locations around the world, Huber's businesses create products used in a
broad range of applications including personal care, food and beverage,
agricultural nutrients and adjuvants, building materials, flame retardants and
smoke suppressants, while also providing sustainable forestry services.
Founded in 1883, Huber is one of the largest family-owned companies based in
the US.

 

For more information, please visit www.huber.com.

 

Important notices

 

This announcement may contain certain forward-looking statements, beliefs or
opinions, including statements with respect to Tate & Lyle's business,
financial condition and results of operations. These forward-looking
statements can be identified by the use of words such as "anticipate",
"expect", "estimate", "intend", "will", "may", "project", "plan", "target" and
"believe" and other words of similar meaning in connection with any discussion
of future events. These statements, by their nature, involve risk, uncertainty
and qualifications because they relate to events and depend upon circumstances
that may or may not occur in the future. A number of factors could cause
actual results and developments to differ materially from those expressed or
implied by the forward-looking statements in this announcement and accordingly
all such statements should be treated with caution. There can be no assurance
that any particular forward-looking information will be realised, and the
performance of Tate & Lyle may be materially and adversely different from
the forward-looking statements. Except where otherwise stated, this
announcement speaks as of the date hereof. Other than in accordance with its
legal or regulatory obligations (including under the Listing Rules, the
Disclosure Guidance and Transparency Rules and the Prospectus Regulation
Rules), Tate & Lyle is not under any obligation and Tate & Lyle
expressly disclaims any intention or obligation (to the maximum extent
permitted by law) to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.

 

This announcement is not intended to, and does not constitute or form part of,
and should not be construed as, any offer, invitation, solicitation or
recommendation of an offer to purchase, sell, subscribe for or otherwise
dispose of or acquire any securities or the solicitation of any vote or
approval in any jurisdiction and neither the issue of the information nor
anything contained herein shall form the basis of or be relied upon in
connection with, or act as an inducement to enter into, any investment
activity. No shares are being offered to the public by means of this
announcement. This announcement does not constitute either advice or a
recommendation regarding any securities, or purport to contain all of the
information that may be required to evaluate any investment in Tate & Lyle
or any of its securities and should not be relied upon to form the basis of,
or be relied on in connection with, any contract or commitment or investment
decision whatsoever. Past performance is not an indication of future results
and past performance should not be taken as a representation that trends or
activities underlying past performance will continue in the future.

 

The distribution of this announcement in jurisdictions in or from certain
jurisdictions may be restricted or prohibited by the laws of any jurisdiction
other than the United Kingdom. Recipients are required to inform themselves
of, and comply with, all restrictions or prohibitions in such other
jurisdictions. Any failure to comply with applicable requirements may
constitute a violation of the laws and/or regulations of other such
jurisdiction.

This announcement has been prepared for the purposes of complying with the
applicable law and regulation of the United Kingdom (including the Listing
Rules and the Disclosure Guidance and Transparency Rules) and the information
disclosed may not be the same as that which would have been disclosed if this
announcement had been prepared in accordance with the laws and regulations of
any jurisdiction outside of the United Kingdom.

 

This announcement is being distributed to all owners of Ordinary Shares and
American Depository Receipts. A copy of this announcement can be found on our
website at www.tateandlyle.com. A hard copy of this statement is also
available from the Company Secretary, Tate & Lyle PLC, 5 Marble Arch,
London WC2B 6AT.

 

Except as explicitly stated, neither the content of Tate & Lyle's website
(or any other website) nor any website accessible by hyperlinks on Tate &
Lyle's website (or any other website) is incorporated in, or forms part of,
this announcement.

 

APPENDIX 1

HUBER REPRESENTATIVES APPOINTED AS NON-EXECUTIVE DIRECTORS OF TATE & LYLE

Tate & Lyle is pleased to announce the appointment of Glenn M. Fish,
Executive Vice President & Chief Financial Officer of Huber, and Cláudia
Vaz de Lestapis, Executive Vice President, General Counsel and Corporate
Secretary of Huber, to the Board as non-executive directors, with effect from
15 November 2024.

 

Mr Fish and Ms Vaz de Lestapis have been nominated to such positions by Huber
pursuant to the Relationship Agreement which provides that Huber shall be
entitled to nominate two non-executive directors of Tate & Lyle for as
long as it holds at least 15% of Tate & Lyle's ordinary shares and one
non-executive director of Tate & Lyle for as long as it holds at least 10%
of Tate & Lyle's ordinary shares, subject in each case to adjustment for
the dilutive impact of certain equity issuances by Tate & Lyle.

 

Mr Fish and Ms Vaz de Lestapis will not be considered independent. Subject to
the terms of the Relationship Agreement, the appointment of each
Huber-appointed director (each a 'Huber Director')  shall be for an initial
term of three years, subject to election by the Company's shareholders at the
Company's next AGM and annual re-election by the Company's shareholders at
each subsequent AGM and to other customary terms and conditions.

 

The Huber Directors shall not be entitled to be appointed as a member of the
Nomination Committee, the Audit Committee or the Remuneration Committee of the
Company, but shall have the right to be invited to attend, as an observer,
formal or informal meetings of the Nomination Committee, the Audit Committee
and the Remuneration Committee.

 

The Huber Directors will not be paid fees for acting as directors of the
Company, but will be reimbursed for reasonable expenses incurred in connection
with their appointments, unless they cease to be employed or engaged by Huber
or any of its affiliates, in which case they shall be entitled to the same
fees as Tate & Lyle's existing non-executive directors.

 

Details of the Huber Directors' appointments to the Board can be found in
Appendix 3 - 1 Directors' service contracts in the announcement of 'Further
information regarding proposed combination of Tate & Lyle and CP Kelco to
create a leading global speciality food and beverage solutions business',
published on 3 October 2024.

 

Other than as disclosed above, no other information is required to be
disclosed pursuant to paragraph 6.4.8R of the Listing Rules in respect of
either appointment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FUREELFFZFLFFBB